CF
AKBA icon

Corebridge Financial’s Akebia Therapeutics AKBA Stock Holding History

Corebridge Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-106,085
Closed -$204K – 101
2025
Q1 		$204K Buy
106,085
+2,663
+3% +$5.44K ﹤0.01% 2065
2024
Q4 		$197K Sell
103,422
-7,807
-7% -$13.6K ﹤0.01% 2199
2024
Q3 		$147K Sell
111,229
-685
-0.6% -$915 ﹤0.01% 2399
2024
Q2 		$115K Buy
+111,914
New +$138K ﹤0.01% 2512

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Corebridge Financial's AKBA Position: Q2 2025 in Review

Corebridge Financial sold out of Akebia Therapeutics (AKBA) in Q2 2025, closing a stake of 106,085 shares — an estimated $204K sold.

Corebridge Financial first reported a position in AKBA in Q2 2024 and held it in 4 quarters. The position peaked at $204K in Q1 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q2 2025.

  • Corebridge Financial reported no remaining Akebia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 106,085 Akebia Therapeutics shares in Q2 2025, an estimated $204K.
  • Corebridge Financial first reported a position in Akebia Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Akebia Therapeutics position peaked at $204K in Q1 2025.
  • 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.